

JC
JCWSCS 1 8 MAR 2004

Mar-18-04 10:44am From-Young And Thompson

703 979 4709

T-726 P.001

F-202

1506-1035-1

VIA FACSIMILE 703/746-9195

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Andreas DIECKMANN et al.

Serial No. 10/620,576

MS PATENT APPLICATION

Filed July 17, 2003

ANTISENSE COMPOUNDS, METHODS AND
COMPOSITIONS FOR TREATING NGAL-
RELATED INFLAMMATORY DISORDERS

REQUEST FOR CORRECTED FILING RECEIPT

Assistant Commissioner for Patents

Alexandria, VA 22313


Sir:

Receipt is acknowledged of the Filing Receipt for
Serial No. 10/620,576, filed July 17, 2003, in the names of
Andreas DIECKMANN et al., in Group 1646.

The declaration filed on February 28, 2004,
listed a fifth inventor. (See enclosed copy).

Certificate of Transmission

I hereby certify that this correspondence if being facsimile transmitted to the
United States Patent and Trademark Office on March 18, 2004.


Amanda L. Goode

DIECKMANN et al. - U.S. Patent Appln. 10/620,576

It is requested that a new Filing Receipt be issued on which the fifth inventor is also listed as:
Liam GOOD, Stockholm, SWEDEN. A Supplemental Application Data Sheet is also enclosed which lists the fifth inventor.

Respectfully submitted,

YOUNG & THOMPSON

By

Benoit Castel

Benoit Castel
Attorney for Applicants
Registration No. 35,041
745 South 23rd Street
Arlington, VA 22202
Telephone: 703/521-2297

March 18, 2004



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/620,576	07/17/2003	1646	941	1506-1035-1	2	39	5

CONFIRMATION NO. 8464

000466
 YOUNG & THOMPSON
 745 SOUTH 23RD STREET 2ND FLOOR
 ARLINGTON, VA 22202

FILING RECEIPT

OC000000011618146

Date Mailed: 01/05/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Andreas Dieckmann, Bromma, SWEDEN;
 Robert Lofberg, Djursholm, SWEDEN;
 Oliver Von Stein, Spanga, SWEDEN;
 Petra Von Stein, Spanga, SWEDEN;
 Liam GOOD, Stockholm, SWEDEN

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/407,954 09/05/2002

Foreign Applications

SWEDEN 0202244-0 07/17/2002

If Required, Foreign Filing License Granted: 10/21/2003

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Antisense compounds, methods and compositions for treating NGAL-related inflammatory disorders

Preliminary Class

536

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).